UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

~~August~~September 126, 2011

Date of Report (Date of earliest event reported)

Poniard Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Washington	0-16614	91-1261311
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)	(CommissionFile No.)	(IRS Employer Identification No.)
750 Battery Street, Suite 330, San Francisco, CA		94111
(Address of principal executive offices)		(Zip Code)

750 Battery Street, Suite 330,

San Francisco, California

94111

(Address of principal executive offices)

(Zip Code)

(650) 583-3774

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 28 – ~~Financial~~Other ~~Information~~Events

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

~~The~~On September 6, 2011, the Company issued a press release ~~dated~~announcing ~~August 12,~~that ~~2011,~~the ~~announcing~~Nasdaq ~~its~~Listing ~~financial~~Qualifications ~~results~~Hearings ~~for~~Panel granted the ~~quarter~~Company’s ~~and~~request ~~six~~for ~~months~~continued ~~ended~~listing ~~June 30,~~of ~~2011.~~its common stock on The ~~full~~Nasdaq ~~text~~Capital Market, subject to satisfaction of ~~the~~certain ~~press~~conditions ~~release~~by isDecember 31, ~~set~~2011, ~~forth~~including ~~in Exhibit~~implementation ~~99.1~~of ~~attached~~a ~~hereto.~~reverse ~~The~~stock ~~press~~split ~~release~~sufficient ~~should~~to beallow ~~read~~the instock ~~conjunction~~to ~~with~~trade above $4.00, completion of the ~~note~~Company’s ~~regarding~~planned ~~forward-looking~~merger ~~statements~~with Allozyne, ~~which~~Inc. isand ~~included~~approval infrom Nasdaq of the ~~text~~combined entity’s application for initial listing on The Nasdaq Capital Market upon completion of the ~~press release~~merger.

~~The~~A ~~information~~copy inof ~~this~~the ~~Item 2.02~~Company’s ~~and~~press release is attached hereto as Exhibit 99.1 toand ~~this~~incorporated ~~Report~~herein ~~will~~by ~~not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934~~reference, asspecifically ~~amended~~including (the ~~“Exchange~~cautionary ~~Act”),~~note orregarding ~~otherwise~~forward-looking ~~subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the~~statements ~~Securities~~contained ~~Act~~in ~~of 1933, as amended, or into another filing under~~ the ~~Exchange~~press ~~Act, unless that filing expressly incorporates this information by reference~~release.

Section 9 – Financial Statements and Exhibits

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits.

99.1 – Press release dated ~~August~~September 126, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Poniard Pharmaceuticals, Inc.
Dated: August 16, 2011	By:	/s/ MICHAEL K. JACKSON
Dated: September 7, 2011	By:	/s/ MICHAEL K. JACKSON
	Name:	Michael K. Jackson
	Title:	Interim Chief Financial Officer ~~(Principal Financial Officer and Principal Accounting Officer)~~

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release dated ~~August~~September 126, 2011

Filing Compare · PONIARD PHARMACEUTICALS, INC.